The Egyptian Drug Authority (EDA) announced the issuance of the National List of High-Alert Medications for 2025, which includes categories of medications that require strict adherence to safe-use procedures due to the potential harm they may cause to the patient if handled incorrectly. This comes within the framework of the Authority's commitment to enhancing awareness among healthcare practitioners and implementing the necessary preventive strategies to reduce medication errors and ensure the safe use of these drugs.

The list includes high-alert medications in the inpatient sections, covering (24) therapeutic classes, in addition to high-alert medications in the outpatient sections, comprising (12) therapeutic classes, ensuring comprehensive coverage of various healthcare environments.

The issuance of these lists is an extension of the Egyptian Drug Authority's scientific and supervisory role. They are prepared and reviewed by specialized scientific committees that include a selection of faculty members from Colleges of Pharmacy and Medicine, and practicing experts in Egyptian health institutions. This contributes to the development of pharmaceutical services and the improvement of the professional competence of the Egyptian pharmacist, supporting the standardization of pharmaceutical practices across the Republic.

Through this issuance, the Authority reaffirms its continuous commitment to achieving patient safety and standardizing pharmaceutical practices by reducing the rates of medication errors and enhancing the safety of drug use within the healthcare system.